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Abstract: Background: A growing trove of literature describes the effect of malnutrition and un-
derweight on the incidence of infammatory bowel disease (IBD). However, evidence regarding 
the association between underweight or obesity and IBD is limited. The study aimed to assess 
the association of body mass index (BMI) with a risk of IBD (Crohn’s disease (CD) and ulcera-
tive colitis (U.C.)) incidence. Methods: We systematically searched PubMed/Medline, Cochrane, 
Web of Science, and Scopus for observational studies assessing the association between BMI and 
IBD that were published up to 30 June 2020. We estimated pooled hazard ratios (HR) with corre-
sponding 95% confdence intervals (CI). Random effect dose-response meta-analysis was performed 
using the variance weighted least-squares regression (VWLS) models to identify non-linear as-
sociations. Results: A total of ten studies involving 15.6 million individuals and 23,371 cases of 
IBD were included. Overall, obesity was associated with an increased IBD risk (HR: 1.20, 95% 
CI: 1.08–1.34, I2 = 0%). Compared to normal weight, underweight (BMI < 18.5 kg/m2) and obesity 
(BMI ≥ 30 kg/m2) were associated with a higher risk of CD, and there was no difference in the 
risk of U.C. among those with BMI < 18.5 kg/m2 and BMI ≥ 30 kg/m2. There was a signifcant 
non-linear association between being underweight and obesity and the risk of development of CD 
(Coef1 = −0.0902, p1 < 0.001 Coef2 = 0.0713, p2 < 0.001). Conclusions: Obesity increases the risk of 
IBD development. Underweight and obesity are independently associated with an increased risk of 
CD, yet there is no evident association between BMI and the risk of U.C. Further studies are needed 
to clarify the underlying mechanism for these fndings, particularly in CD. 
Keywords: obesity; body mass index; infammatory bowel disease; Crohn’s disease; systematic 
review; meta-analysis; dose-response analysis 
1. Introduction 
Globally, there has been a precipitous rise in the incidence of infammatory bowel 
disease (IBD) in newly industrialized countries, particularly in younger populations [1]. 
Historically, IBD has been associated with malnutrition and underweight [2]. Indeed, 
the major forms of IBD, Crohn’s disease (CD) and ulcerative colitis (U.C.), are enig-
matic infammatory disorders and cause progressive damage to the gastrointestinal tract, 
which leads to chronic underweight status [3]. Moreover, existing data suggest that around 
65–75% of patients with CD and U.C. (18–62%) are underweight [4]. 
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Toward the end of the twentieth century, obesity emerged as an adverse prognostic 
factor of various chronic infammatory diseases, including IBD [5]. Current data on the 
role of obesity in IBD development are inconclusive; indeed, studies have shown a positive 
correlation between IBD and obesity, where 32.7% of IBD patients are obese (30.3% of CD 
and 35.2% of U.C.) [6]. Moreover, obesity is associated with perianal complications of CD, 
higher rates of relapse, and hospitalization [7,8], and several cohort studies have reported 
that obesity is associated with an increased risk of developing CD but not U.C. [9–13]. 
However, limited data are characterizing the impact of obesity on the development of 
U.C., suggesting that obesity may be higher or not associated with an increased risk of 
U.C. [14,15], although this has not been consistently reported [9–17]. 
The infuence of body mass index (BMI) and the development of IBD has previously 
been documented in epidemiological evidence, with no evidence of the association be-
tween increasing B.M.I. and IBD development in the European Prospective Cohort Study 
(EPIC) [15]. Moreover, two prior meta-analyses were conducted on this topic, where the 
study by Dang et al. included 24 studies that identifed a signifcant difference in the BMI 
of patients with IBD in the active phase [18], and Rahmani et al. reported obesity as a 
signifcant risk factor for the development of CD [19]. In contrast, a recent retrospective 
study [20] reported an absolute increase in the incidence of CD among middle-aged adults 
from 1.71% in those with BMI < 18.5 kg/m2 to 0.73% in BMI > 25 kg/m2. Considering the 
evolving epidemiology of IBD, identifying and controlling the modifable risk factors offers 
disease prevention avenues. Thus, this systematic review and meta-analysis aimed to 
assess body mass index association with the risk of development of IBD (CD and U.C.). 
2. Materials and Methods 
2.1. Data Source and Search Strategy 
We performed a systematic review and meta-analysis following the guidelines of 
the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) [21]. 
A comprehensive literature search was conducted to identify the observational studies 
investigating the association between body mass index with IBD in the adult population, 
via PubMed/Medline, Cochrane Library, Web of Science, and Scopus, up to June 2020. 
A detailed search string using different combinations of MeSH (Medical Subjects Headings) 
keywords, using the Boolean operators “AND” and “OR”, was conducted to identify the 
studies (Supplementary Table S1). 
All of the articles and relevant reviews published in English as full peer-reviewed 
manuscripts were screened for potential missing studies. The process was independently 
conducted by two reviewers (A.S.B. and J.R.), and the identifed studies were evaluated 
for analysis suitability. After eliminating duplicates, titles and abstracts were screened 
to exclude the irrelevant studies. All observational cohort studies eligible for the present 
study were scrutinized thoroughly, and studies that met selection criteria were retrieved 
for further analysis. 
2.2. Inclusion and Exclusion Criteria 
Studies were eligible for inclusion according to the following criteria: (1) peer-
reviewed articles published in English, with participants aged >18 years; (2) observational 
cohort studies evaluating the association between BMI and concerning the risk of IBD (CD 
and/or U.C.); (3) reported the association as odds ratio (OR), risk ratio (R.R.), or hazard 
ratio (HR), with corresponding 95% confdence intervals (CI) were included. 
Studies were excluded if they were conducted on children or on patients with a diag-
nosis of other gastrointestinal disorders, did not incorporate suffcient data of OR/RR/HR 
to include in the meta-analysis or estimates to compute with 95% CI, and did not stratify 
according to BMI. Furthermore, in vitro and non-human studies, case reports, case series, 
editorials, letters, interventional studies, review articles, and non-peer-reviewed articles 
without suffcient data were also excluded. 
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2.3. Data Extraction and Quality Assessment 
The information was extracted from each study, independently and blinded by A.S.B., 
C.C.C., and J.R., and discrepancies were discussed by all authors and resolved through 
a consensus. The following information was extracted: frst author, year of publication, 
study location, study design, sample size, mean age and gender of the study partici-
pants, duration of the follow-up, confounding factors, and summary estimates with the 
corresponding 95% CI of IBD risk. Data from fully adjusted models were used for the 
meta-analysis. 
The quality of each study was assessed according to the Newcastle-Ottawa quality 
assessment Scale (N.O.S.) [22], evaluating three factors: patient selection, comparability of 
study groups, and the assessment of outcomes. An aggregated score of 6.5 to 9 indicates 
high quality, while 0–6 designates low quality. 
2.4. Data Synthesis and Statistical Analysis 
The meta-analysis was performed using STATA software (version 16, STATA Corpora-
tion, College Station, TX, USA), using a DerSimonian and Laird multivariate random-effects 
model to combine the risk estimates of IBD [23]. Normal BMI was considered a reference 
category to investigate IBD’s risk in association with underweight and obesity. When the 
study did not provide the reference category’s data, the mean or median of each BMI 
category was used. Heterogeneity between the studies was estimated using the Cochran Q 
test (Pheterogeneity) and I2 statistics; Pheterogeneity ≤ 0.10 and/or I2 > 50% indicates signifcant 
heterogeneity. To examine the potential non-linear association between BMI and IBD risk, 
we used restricted cubic splines with three knots at the fxed percentiles of 10%, 50%, 
and 90% of exposure data [24]. Statistical signifcance was accepted at p < 0.05. Funnel 
plots, Begg’s rank correlation test, and Egger’s regression asymmetry test were used to 
evaluate the publication bias. 
3. Results 
3.1. Study Selection and Characteristics 
The search strategy yielded a total of 1835 articles, among which 1796 were designated 
as not pertinent to the study purpose (Figure 1). After examining 39 full-text articles, 
29 were excluded because they did not meet the inclusion criteria (Supplementary Materi-
als). Finally, a total of 10 studies were eligible for inclusion, comprising 15,598,438 partici-
pants, and these were pooled into the meta-analysis [9–17,20]. 
The core characteristics of the included studies are presented in Table 1. Six stud-
ies were performed in Europe [9–11,13,15,17], two in the United States [12,16], and one 
each in Korea [20] and Japan [14]. The studies were published between 2013 [15] and 
2020 [20]. Six studies were prospective cohorts [9–12,15,17], while four were retrospec-
tive [13,14,16,20]. Eight studies reported the cases of both CD and U.C. [9–13,15,17], one fo-
cused on U.C. [14], and one study reported the risk of CD in adults and the elderly [20]. 
The mean age of the study population was 35 years, and the median duration of follow-up 
was 13.4 years. Three studies were conducted on women [11–13], two among men [9,17], 
and others included participants from both genders [10,14–16,20]. Participants included 
in these studies reported a total of 23,371 cases of IBD, comprising 6097 cases of CD and 
17,274 cases of U.C. 
Healthcare 2021, 9, 35 4 of 12 




Figure 1. Flow chart of included studies. 
The core characteristics of the included studies are presented in Table 1. Six studies 
were performed in Europe [9–11,13,15,17], two in the United States [12,16], and one each 
in Korea [20] and Japan [14]. The studies were published between 2013 [15] and 2020 [20]. 
Six studies were prospective cohorts [9–12,15,17], while four were retrospective 
[13,14,16,20]. Eight studies reported the cases of both CD and U.C. [9–13,15,17], one fo-
cused on U.C. [14], and one study reported the risk of CD in adults and the elderly [20]. 
The mean age of the study population was 35 years, and the median duration of follow-
up was 13.4 years. Three studies were conducted on women [11–13], two among men 
[9,17], and others included participants from both genders [10,14–16,20]. Participants in-
cluded in these studies reported a total of 23,371 cases of IBD, comprising 6097 cases of 
CD and 17,274 cases of U.C. 
  
Figure 1. Flow chart of included studies. 
3.2. Primary Meta-Analysis 
3.2.1. Association Between BMI and Development of IBD 
Five studies provided the data of obesity [9–13] and underweight [10–12,17] and the 
development of IBD [9–13]. Compared to normal weight, our meta-analysis identifed that 
obesity was signifcantly associated with an increased risk of IBD development by 20% 
(HR: 1.20, 95% CI: 1.08–1.34, I2 = 0%) (Figure 2) but not underweight (HR: 1.07, 95% CI: 
0.98–1.16, I2 = 0%). 
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Table 1. Core characteristics of studies included in the meta-analysis [9–17,20]. 
IBD 








Size CD UC 
† 
Moon, J. M. 
et al. [20] 2020 Korea 50 Both Retrospective 7.3 14,060,821 977 - 8 
Mendall, M. A. 
et al. [9] 2019 Denmark 19 Male Prospective 38 377,957 1523 3323 9 
Jensen, C. B. 
et al. [10] 2018 Denmark 46 Both Prospective 38 316,799 1500 2732 7 
Mendall, M. 
et al. [11] 2018 Denmark 30 Female Prospective 6 74,512 137 448 8 
Kuwahara, E. 
et al. [14] 2017 Japan 42 Both Retrospective 2 39,554 - 8120 9 
Flores, A. et al. 
[16] 2015 U.S.A. 40 Both Retrospective 5 581 297 284 8 
Melinder, C. 
et al. [17] 2015 Sweden 18 Male Prospective 4 240,984 986 1878 9 
Khalili, H. 
et al. [12] 2015 U.S.A. 34 Female Prospective 18 111,498 153 229 8 
Harpsøe, M. C. 
et al. [13] 2014 Denmark 30 Female Retrospective 11 75,008 138 394 8 
10 Euro-
Chan, S. S. 
et al. [15] 2013 
pean 
coun- 52 Both Prospective 5.1 300,724 75 177 9 
tries 
† Newcastle-Ottawa scale; IBD—Infammatory bowel disease; CD—Crohn’s disease; U.C.—Ulcerative colitis. 
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3.2.2. Association Between BMI and Crohn’s Disease 
Seven studies provided underweight data versus the normal weight category of BMI 
and risk of CD from 15,257,579 participants [9–13,17,20]. With normal BMI as the reference, 
it was observed that a BMI < 18.5 kg/m2 poses a relatively higher risk of CD development 
(HR: 1.29, 95% CI: 1.10–1.51, I2 = 43.2%) (Figure 3). 




Figure 3. Association between underweight (BMI <18.5 kg/m2) and risk of Crohn’s disease. 
There were seven studies, with 1,257,079 participants, that reported the risk of CD 
among obese patients [9–13,15,16]. A significant increase in HR was observed in those 
with BMI ≥30 kg/m2 compared with those with normal BMI (HR: 1.25, 95% CI: 0.94–1.65, 
I2 = 49.3%) (Figure 4). 
Figure 3. Association between underweight (BMI < 18.5 kg/m2) and risk of Crohn’s disease. 
There were seven studies, with 1,257,079 participants, that reported the risk of CD 
among obese patients [9–13,15,16]. A signifcant increase in HR was observed in those 
with BMI ≥ 30 kg/m2 compared with those with normal BMI (HR: 1.25, 95% CI: 0.94–1.65, 
I2 = 52%) (Figure 4). 
3.2.3. Association Between BMI and Ulcerative Colitis 
Seven studies including 1,236,312 participants were pooled to evaluate the risk of U.C. 
among patients with a BMI < 18.5 kg/m2 [9–14,17] and showed no signifcant difference in 
developing U.C. as compared with those with normal BMI (HR: 1.04, 95% CI: 0.97–1.13, 
I2 = 0.0) (Figure 5). 
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Figure 5. Association between underweight (BMI < 18.5 kg/m2) and risk of ulcerative colitis. 
Similarly, eight studies [9–16], with a total of 1,296,633 participants, reported the risk 
of U.C. in those with a higher BMI ≥ 30 kg/m2 and suggested the absence of a relationship 
between obesity and an increased risk of U.C. development (HR: 0.95, 95% CI: 0.77–1.16), 
with a signifcant and high heterogeneity (51.1%, p = 0.046) (Figure 6). 
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3.4. Quality of Studies 
All included studies displayed high quality, with N.O.S. scores ranging from 7 to 9. 
All studies were observed to have drawn the cases and controls from the same community 
and reported BMI. The majority of the studies provided data from a representative popula-
tion and detailed the baseline and outcome exposure outcomes. Only one study did not 
meet the criteria for adequate assessment of the outcome of interest at baseline and did not 
report the baseline information [10]. 
3.5. Publication Bias 
Despite the heterogeneity in the outcomes of CD and U.C., the publication bias funnel 
plots were found to be symmetrical. Additionally, no evidence of publication bias was 
identifed in the primary meta-analysis in Egger’s regression asymmetry test and Begg’s 
rank correlation test (Supplementary Figure S1a–f). 
4. Discussion 
Worldwide, the ongoing unprecedented shift in the BMI paradigm has led to an 
inexorable increase in the prevalence of obesity; additionally, approximately 15–40% of IBD 
patients are obese [23]. On the other hand, underweight and malnutrition have been associated 
with IBD [24]; however, the association of underweight or obesity on the presentation and 
course of IBD remains equivocal. Given the increasing prevalence in the onset of IBD among 
young adults, understanding BMI’s association is of paramount importance. The principal 
fndings of our meta-analysis of 10 cohort studies showed a direct association between 
BMI (both lower BMI and higher BMI) and risk of IBD, particularly CD. At the same 
time, no relationship was found between BMI and risk of U.C. Moreover, this association 
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was further strengthened by the dose-response analysis, confrming a signifcant non-
linear association between BMI and CD’s risk, but not U.C. This lack of association is an 
important message to disseminate considering the results of the present meta-analysis, 
which indicates that obesity may be a contributory factor in the development of CD but 
not U.C. 
In the present study, the included articles were contemporary cohorts, all published be-
tween 2013 and 2020, which included an equitable number of prospective and retrospective 
studies, with an appropriately long median follow-up (≈13 years). A total of nine out of ten 
studies reported the association between BMI and the development of CD [9–13,15–17,20], 
while nine investigated the risk of U.C. [9–17]; one study was conducted across 10 Euro-
pean countries [15], one each in Japan [14], Sweden [17], and Korea [20], two in the United 
States [12,16], and four in Denmark [9–11,13]. 
Five studies, with a total of 879,959 individuals, were included in the dose-response 
analysis and reported the risk of CD and U.C. based on the BMI [9,11–13,17]. The re-
sults of the included studies suggested an increased risk of CD in participants with a 
BMI < 18.5 kg/m2 (HR: 1.29, 95% CI: 1.10–1.51, I2 = 43.2%) and BMI ≥ 30 kg/m2 (HR: 1.25, 
95% CI: 0.94–1.65, I2 = 52%). A clear dose-response association was determined between 
BMI and CD and U.C. development in the non-linear model. Notably, we observed a 
paradoxical relationship in which both low and high BMI are strongly associated with a 
signifcantly increased risk of CD. Based on our analysis, there is an increased risk of CD in 
those with low BMI and high B.M.I., compared to normal BMI; additionally, several other 
studies support these results [11,13,20]. 
In general, obesity is linked with a chronic, low-grade, pro-infammatory state, and it 
is considered an adverse prognostic factor in various chronic infammatory diseases, 
including IBD [25]. While there is a range of potential pathways associated with CD 
development in those affected by obesity, the presence of mesenteric fat increases resistin 
secretion from macrophages and leukocytes. In addition, leptin secretion from adipocytes 
may contribute to increasing levels of infammatory cytokines, such as tumor necrotic 
factor-α, and interleukin-1 and -6 [25–29]. Furthermore, both obesity and IBD are associ-
ated with increased gut bacterial translocation and dysbiosis [27,30]. Recently, Szilagyi’s 
review greatly described the pro-infammatory pathogenic mechanism between obesity 
and IBD and noted specifc possible interactions in both IBD and obesity [31] that can 
merit further investigation. A low BMI is associated with several nutritional defcien-
cies, micronutrients (iron, calcium, zinc, copper, magnesium, and selenium) and vitamins, 
such as A, D, K, B12, and folic acid, which are the main determinants for the development 
of IBD [4,32,33]. Thereby, both low and high BMI may introduce a two-fold challenge to 
the increasing IBD burden. 
In this meta-analysis, both underweight and obesity were not associated with the 
development of U.C. This lack of association between BMI and U.C. may be due to the 
differences in the U.C. characteristics, such as the ulcerations being limited to the colon, 
the extent of mucosal damage, differences in the clinical presentation, and the extent of 
intestinal involvement. However, Kuwahara et al. reported an inverse association between 
a high BMI and the risk of U.C. exacerbation [14]. Although this putative relationship 
warrants further elucidation, it is important to note that just a single study reported that a 
high BMI is associated with an increased risk of U.C. Therefore, these results should be 
replicated, preferably in case-control settings, to better understand the etiology of IBD in 
individuals with obesity. 
Strengths and Limitations 
There are several signifcant strengths of our meta-analysis that should be noted. 
Firstly, the present study has provided deeper clarity into the effect of BMI on CD and U.C. 
by integrating the results from 10 cohort studies, with an unprecedented, extremely large 
sample size, consisting of 15.6 million participants. This sample size yielded generalizable 
fndings and the opportunity for subsequent dose-response analysis. Second, the current 
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study was free from signifcant publication bias, low heterogeneity, and symmetrical funnel 
plots, suggesting that the study fndings are reliable. A possible limitation of this study is 
BMI as a clinical marker; it is indeed worth considering signifcant confounders that may 
exist within the compiled studies. Lastly, it is important to note that all the included studies 
are observational cohorts in design. We must consider the possibility of misclassifcation 
bias. Participants in the cohort may suffer an array of additional comorbidities that may 
have impacted somewhat in the meta-analysis. 
5. Conclusions 
Underweight and obesity are associated with the development of CD, yet no asso-
ciation between BMI and the risk of U.C. was evident. The dose-response meta-analysis 
demonstrated that increased BMI was associated with an increased risk of CD, and the 
curve becomes steeper with increasing BMI. Further studies are needed to discern and 
clarify the underlying mechanism for these fndings. 
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